Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Flutamide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    62 result(s) found for: Flutamide. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2005-004163-39 Sponsor Protocol Number: HSJD-LIT-05 Start Date*: 2005-11-14
    Sponsor Name:Hospital Sant Joan de Déu
    Full Title: Effects on Endocrine-Metabolic Parameters and Body Composition of the Addition of Low-Dose Pioglitazone to Flutamide-Metformin Therapy in Young Women with Hyperinsulinemic Ovarian Hyperandrogenism ...
    Medical condition: Polycystic Ovary Syndrome includes anovulatory hyperandrogenism, hyperinsulinemia and/or dyslipidemia. Adiponectin and interleukin-6 are adipocytokines that have been related to abdominal fat exces...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000299-15 Sponsor Protocol Number: BC1-03 Start Date*: 2004-11-03
    Sponsor Name:Algeta AS
    Full Title: A double-blind, dose-response, phase II, multicentre study of radium-223 (Alpharadin TM ) for the palliation of painful bone metastases in hormone refractory prostate cancer patients
    Medical condition: The target population is patients suffering from bone pain due to skeletal metastasis secondary to prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002149-36 Sponsor Protocol Number: G-202-002 Start Date*: 2012-12-10
    Sponsor Name:GenSpera, Inc.
    Full Title: An Open-Label, Single-Arm, Phase 2 Study of G-202 in Patients with Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
    Medical condition: chemotherapy-naïve metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002027-13 Sponsor Protocol Number: DPSA05 Start Date*: 2005-07-22
    Sponsor Name:Royal Marsden NHS FOundation Trust
    Full Title: A phase I/II study of docetaxel plus prednisolone plus diethylstilbestrol plus aspirin in androgen-independent prostate cancer
    Medical condition: Hormone refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-006018-16 Sponsor Protocol Number: Start Date*: 2006-02-27
    Sponsor Name:Royal Marsden Hospital
    Full Title: A Randomised Phase III Trial Of Low Dose DailyDexamethasone Versus Intermittent Dexamethasone Versus Prednisolone In Hormone Refractory Prostate Cancer
    Medical condition: Hormone refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002210-36 Sponsor Protocol Number: PR2006-03 Start Date*: 2006-11-10
    Sponsor Name:Queen Mary University of London
    Full Title: A Phase II study evaluating intravenous Melphalan with autologous whole blood stem cell transplantation (PBSCT) in patients with Androgen –Independent Prostate Cancer (AIPC)
    Medical condition: Open-labelled, non-randomised, treatment intensifying cohort study in androgen-independent prostate cancer (AIPC.)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003087-59 Sponsor Protocol Number: EFC6193 Start Date*: 2006-11-29
    Sponsor Name:sanofi aventis recherche et developpement
    Full Title: A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combination With Prednisone For The Treatment of Hormone ...
    Medical condition: Hormone Refractory Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) BE (Completed) NL (Completed) SK (Completed) DK (Completed) SE (Completed) FI (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003191-23 Sponsor Protocol Number: ANZUP1303 Start Date*: 2014-11-07
    Sponsor Name:Cancer Trials Ireland
    Full Title: Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD
    Medical condition: Localised prostate cancer at high risk of recurrence
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Completed) AT (Trial now transitioned) ES (Ongoing) SI (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004756-20 Sponsor Protocol Number: EFC6546 Start Date*: 2007-09-19
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastat...
    Medical condition: Patients with metastatic androgen-independent prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) SE (Completed) CZ (Completed) PT (Completed) ES (Completed) DK (Completed) HU (Completed) EE (Completed) BE (Completed) NL (Completed) IT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003190-42 Sponsor Protocol Number: ANZUP1304 Start Date*: 2014-10-17
    Sponsor Name:Cancer Trials Ireland
    Full Title: Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET
    Medical condition: Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-005364-65 Sponsor Protocol Number: Start Date*: 2007-06-27
    Sponsor Name:AUO
    Full Title: Intermittent Treatment with Taxotere and Prednisone in patients with asymptomatic, hormone-refractory prostate cancer: A Multicenter Phase II Trial
    Medical condition: asymptomatic hormone-refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005249-21 Sponsor Protocol Number: 1239.3 Start Date*: 2006-02-16
    Sponsor Name:Boehringer Ingelheim Ltd.
    Full Title: A multi-centre 3-arm randomized phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancer
    Medical condition: Chemo-naive hormone refractory prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001166-13 Sponsor Protocol Number: COU-AA-001 Start Date*: 2005-09-21
    Sponsor Name:Cougar Biotechnology, Inc
    Full Title: A Phase I/II Open Label Study of the 17α-hydroxylase/ C17,20 lyase inhibitor, Abiraterone acetate, in Patients with Prostate Cancer who have failed hormone therapy
    Medical condition: Hormone refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    8.0 10062904
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000351-14 Sponsor Protocol Number: PR201206 Start Date*: 2012-10-24
    Sponsor Name:Barts Health NHS Trust
    Full Title: A PHASE II STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT) OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
    Medical condition: castration resistant prostate cancer patients
    Disease:
    Population Age: Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005255-18 Sponsor Protocol Number: 1216.19 Start Date*: 2006-07-03
    Sponsor Name:Boehringer Ingelheim UK Ltd
    Full Title: A single arm phase II study to investigate the efficacy, safety and pharmacokinetics of a single dose of 200 mg of i.v. BI 2536, administered once every 3 weeks in patients with advanced metastatic...
    Medical condition: Advanced Metastatic Hormone Refractory Prostate Cancer
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-002370-64 Sponsor Protocol Number: AUPSG 01/07 Start Date*: 2007-06-11
    Sponsor Name:Austrian Prostate Study Group (AUPSG)
    Full Title: Multi-center, randomized, double-blind phase II study of sorafenib or placebo with best supportive care after failure of deocetaxol in metastatic hormone-refractory prostate cancer
    Medical condition: metastatic hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004545-15 Sponsor Protocol Number: MLAM 2007/01 Start Date*: 2008-06-10
    Sponsor Name:University Medical Center Utrecht
    Full Title: The Split Dose Study: Split dose Rhenium-188-HEDP regimen in hormone refractory prostate cancer patients with bone metastases; a phase I toxicity study and phase II efficacy study.
    Medical condition: Hormone refractory prostate cancer with painful bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003228-20 Sponsor Protocol Number: 155-CL-007 Start Date*: 2006-01-12
    Sponsor Name:Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V by August 2005)
    Full Title: A PHASE II, MULTI-CENTER, OPEN-LABEL STUDY OF YM155 IN SUBJECTS WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) PREVIOUSLY TREATED WITH AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
    Medical condition: Male adults with Hormone Refractory Prostate Cancer who have progressed, as evidenced by PSA progression or progression of measurable disease, after at least 1 prior chemotherapy regimen.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10062904 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-004322-24 Sponsor Protocol Number: ARN-509-003 Start Date*: 2013-08-27
    Sponsor Name:Aragon Pharmaceuticals, Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
    Medical condition: Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Trial now transitioned) FI (Completed) SE (Completed) NL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NO (Completed) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) HU (Completed) CZ (Trial now transitioned) SK (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004429-17 Sponsor Protocol Number: CO39303 Start Date*: 2018-09-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/...
    Medical condition: Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Completed) PT (Completed) DE (Completed) DK (Completed) HU (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IE (Completed) BE (Completed) ES (Ongoing) GR (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 12:09:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA